James River Group Holdings, Inc. (JRVR) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001620459 · SEC filings checked Oct 18, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 10, 2026 | $161.3M | $6.4M | $0.10 | Filing |
| Mar 31, 2026 | May 4, 2026 | $151.4M | $-8.9M | $-0.23 | Filing |
| Dec 31, 2025 | Mar 2, 2026 | $167.7M | $32.1M | $0.59 | Filing |
| Sep 30, 2025 | Nov 3, 2025 | $172.7M | $1.0M | $-0.02 | Filing |
| Jun 30, 2025 | Aug 4, 2025 | $174.8M | $4.8M | $0.06 | Filing |
| Mar 31, 2025 | May 5, 2025 | $172.3M | $9.6M | $0.16 | Filing |
| Dec 31, 2024 | Mar 3, 2025 | $126.7M | $-64.8M | $-2.44 | Filing |
| Sep 30, 2024 | Nov 12, 2024 | $191.5M | $-39.4M | $-1.10 | Filing |
What would James River Group Holdings, Inc. have to report for its valuation to change?
At $3.82, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about -5.8% a year, to $0.33. On that path the next quarter needs diluted EPS near $-0.02, against $-0.02 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | -5.8% | -5.8% |
| EPS needed in final year | $0.33 | $0.33 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. JRVR goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.